| Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates in the allergy, respiratory, and opioid overdose markets include: SYMJEPI (epinephrine) Injection 0.3mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis; ZIMHI (naloxone HCL Injection, USP) five mg/0.5 mL for the treatment of opioid overdose; and Tempol, an investigational drug. Co. also has a microbicide product candidate, named C31G. We show 43 historical shares outstanding datapoints in our ADMP shares outstanding history coverage, used to compute ADMP market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADMP market cap history over the course of time is important for investors
interested in comparing ADMP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADMP versus a peer is one thing; comparing
ADMP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADMP can fluctuate over the course of history.
With this page we aim to empower investors researching ADMP by allowing them to research the ADMP market cap history.